| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
551.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 18.6 |
| Insider 6 Months : 18.6 |
| Insider 3/6 Months : 37.7 |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
| Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
1,254 |
20,641 |
171,008 |
| Total Sell Value |
$0 |
$10,922 |
$205,329 |
$1,825,540 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
10 |
20 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mammen Mathai |
SVP, Research & Development |
• – – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
130,000 |
228,530 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
176,590 |
|
- |
|
| Haumann Brett K |
SVP, Clinical Development |
• – – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
135,000 |
140,714 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
208,473 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
521,581 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(660) |
25,724 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2014-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(658) |
80,492 |
|
- |
|
| Lee Junning |
Sr. VP, Technical Operations |
• – – |
2014-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(657) |
53,962 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. OfficerOffi |
• – – |
2014-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,435 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2014-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
81,150 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2014-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,384 |
|
- |
|
| Lee Junning |
Sr. VP, Technical OperationsOf |
• – – |
2014-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
54,619 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2014-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
57 |
521,638 |
|
- |
|
| Gala Renee D |
SVP-Finance |
• – – |
2014-08-20 |
4 |
D |
$26.98 |
$4,263 |
D/D |
(158) |
14,279 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2014-06-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(436,802) |
8,299,218 |
|
- |
|
| Theravance Inc |
10% Owner |
– – • |
2014-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(33,100,000) |
0 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2014-05-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,736,020 |
|
- |
|
| Theravance Inc |
10% Owner |
– – • |
2014-05-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,100,000 |
|
- |
|
543 Records found
|
|
Page 22 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.13 (1.53%) 
